{
    "clinical_study": {
        "@rank": "164875", 
        "arm_group": [
            {
                "arm_group_label": "ATRA+Arsenic", 
                "arm_group_type": "Experimental", 
                "description": "Patients received treatment with retinoic acid and arsenic trioxide"
            }, 
            {
                "arm_group_label": "ATRA+chemo", 
                "arm_group_type": "Active Comparator", 
                "description": "patients recieved retinoic acid and chemotherapy with idarubicin or daunorubicin"
            }
        ], 
        "brief_summary": {
            "textblock": "In this prospective randomized study for patients with newly diagnosed acute promyelocytic\n      leukemia, patients will be randomized into two groups which received retinoic acid and\n      arsenic trioxide based treatment versus retinoic acid and chemotherapy based regimen."
        }, 
        "brief_title": "Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Promyelocytic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Promyelocytic, Acute"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this prospective randomized study for patients with newly diagnosed acute promyelocytic\n      leukemia. For induction, all patients will be randomized into two groups which received\n      treatment composed of retinoic acid combined with arsenic trioxide versus retinoic acid\n      combined with chemotherapy. For consolidation, the experimental group recieved 2 cycles of\n      ATRA+arsenic and control group recieved two cycles of ATRA+idarubicin or daunorubicin. After\n      consolidation, all patients achieved molecular remission will recieved 5 cycles of\n      maintenance treatment with ATRA and arsenic. In case of intermediate or high-risk disease,\n      cytarabine will be add for consolidation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  newly-diagnosed patients with acute promyelocytic leukemia via cytogenetics and\n             molecular assay\n\n          -  Age: 18-65\n\n          -  Hepatic/renal function: Bil\u226435\u03bcmol/L\uff0cAST/ALT less than 2Xnormal range, Cr 150\u03bcmol/L\n\n          -  Normal cardial function\n\n          -  Informed consent\n\n        Exclusion Criteria:\n\n          -  Relapsed patients\n\n          -  Known history of arsenic allergy\n\n          -  QT interval >450ms\n\n          -  Other malignanct disease\n\n          -  Pregnant patients\n\n          -  Patients with mental illness"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "680", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01987297", 
            "org_study_id": "APL2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "ATRA+Arsenic", 
                "description": "experimental", 
                "intervention_name": "ATRA+arsenic", 
                "intervention_type": "Drug", 
                "other_name": "retinoic acid + arsenic trioxide"
            }, 
            {
                "arm_group_label": "ATRA+chemo", 
                "description": "control", 
                "intervention_name": "ATRA+chemo", 
                "intervention_type": "Drug", 
                "other_name": "retinoic acid + idarubicin or daunorubicin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Daunorubicin", 
                "Idarubicin", 
                "Arsenic trioxide", 
                "Tretinoin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "arsenic", 
            "acute promyelocytic leukemia", 
            "outcome"
        ], 
        "lastchanged_date": "November 12, 2013", 
        "location": {
            "contact": {
                "email": "hujiong@medmail.com.cn", 
                "last_name": "Jiong HU"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200025"
                }, 
                "name": "Department of Hematology"
            }, 
            "investigator": {
                "last_name": "Jun-min Li, M.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Combined Retinoic Acid,Arsenic Trioxide and Chemotherapy for Newly-diagnosed Acute Promyelocytic Leukemia: Chinese National Multi-center Randomized Study", 
        "other_outcome": {
            "measure": "arsenic associated toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "5 year"
        }, 
        "overall_contact": {
            "email": "hujiong@medmail.com.cn", 
            "last_name": "Jiong HU"
        }, 
        "overall_official": {
            "affiliation": "Department of Hematology, Rui Jin Hospital, Shanghai JiaoTong University School of Medicine", 
            "last_name": "Jun-min Li, M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "disease free survival", 
            "safety_issue": "No", 
            "time_frame": "3 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01987297"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Jiao Tong University School of Medicine", 
            "investigator_full_name": "Jiong HU", 
            "investigator_title": "Deaprtment of Hematology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "3 year"
        }, 
        "source": "Shanghai Jiao Tong University School of Medicine", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Shanghai First People's Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Peking University People's Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Shanghai Jiao Tong University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}